Rangeley Capital’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRO
Rangeley Capital's SPRO Position: Q3 2026 in Review
Rangeley Capital opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 17,202 shares worth $20.8K. The stake represents 0.03% of the portfolio and ranks #129 among its holdings. This is a return to the name: Rangeley Capital previously reported a position in SPRO as recently as Q3 2025.
Rangeley Capital first reported a position in SPRO in Q3 2025 and has held it in 2 quarters since. The position peaked at $56.4K in Q3 2025. 61 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.
- Rangeley Capital held 17,202 shares of Spero Therapeutics worth $20.8K as of Q3 2026.
- Spero Therapeutics was a new Rangeley Capital position in Q3 2026.
- Spero Therapeutics made up 0.03% of Rangeley Capital's portfolio in Q3 2026, its #129 holding.
- Rangeley Capital first reported a position in Spero Therapeutics in Q3 2025 and has held it in 2 quarters since.
- Rangeley Capital's Spero Therapeutics position peaked at $56.4K in Q3 2025.
- 61 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.
Based on Rangeley Capital's 13F filing for Q3 2026, filed 16 Nov 2026.